Back Pain News and Research

Latest Back Pain News and Research

New study finds growing use of CAM therapies among menopausal women

The use of complementary and alternative medicine (CAM) is increasing for the treatment of menopausal symptoms but often without the guidance of a clinician. That's according to a new study reported online today in Menopause, the journal of the North American Menopause Society.

10 Jun 2015

People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health as rates of nonfatal diseases and injuries - including diabetes and hearing loss - decline more slowly than death rates, according to a new analysis of 301 diseases and injuries in 188 countries.

9 Jun 2015

GBD analysis shows over 95% of global population has health problems

Just one in 20 people worldwide (4·3%) had no health problems in 2013, with a third of the world's population (2·3 billion individuals) experiencing more than five ailments, according to a major new analysis from the Global Burden of Disease Study (GBD) 2013, published in The Lancet.

8 Jun 2015

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

2 Jun 2015

North American Spine Society issues formal coverage recommendation for MIS SI joint fusion

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System®, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that the North American Spine Society (NASS) has issued their formal coverage recommendation for MIS SI joint fusion titled "Percutaneous Sacroiliac Joint Fusion, Defining Appropriate Coverage Positions."

1 Jun 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.

30 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Nevro Corp., a medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has received approval from the United States Food and Drug Administration for its Senza spinal cord stimulation (SCS) system.

10 May 2015

Study shows link between upright locomotion and spinal health

A Simon Fraser University researcher has uncovered what may be the first quantified evidence demonstrating a relationship between upright locomotion and spinal health.

28 Apr 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

Two UC Davis researchers awarded grant to help improve surveillance for patients with small lung nodules

Two UC Davis researchers will help run a major national study to improve surveillance practices for patients with small lung nodules identified on CT imaging and extremely low risk for lung cancer.

16 Apr 2015

Board-certified physiatrist Brian Fellechner joins St. Luke’s University Health Network

St. Luke’s University Health Network is pleased to welcome board-certified physiatrist Brian Fellechner, DO, to its medical staff. A graduate of the Philadelphia College of Osteopathic Medicine, Dr. Fellechner completed his residency in physical medicine and rehabilitation at the University of Medicine and Dentistry of New Jersey – New Jersey Medical School in Newark, New Jersey where he served as chief resident at the Kessler Institute for Rehabilitation.

15 Apr 2015

ACA calls for 'conservative care first' approach to low-back pain

The American Chiropractic Association, in response to recent research calling into question the efficacy of acetaminophen in the management of spinal pain, strongly encourages patients and healthcare providers to consider the benefits of a conservative approach to back pain.

13 Apr 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Early and guideline adherent physical therapy reduces costs, resources in LBP patients

A study in the scientific journal BMC Health Services Research shows that early and guideline adherent physical therapy following an initial episode of acute, nonspecific low back pain (LBP) resulted in substantially lower costs and reduced use of health care resources over a 2-year period.

10 Apr 2015

National study comparing minimally invasive lumbar decompression (mild) with epidural steroid injections (ESIs) reaches full enrollment

Lumbar spinal stenosis is primarily a degenerative, age-related narrowing of the lower spinal canal resulting in compression of the nerve roots. MILD treats this compression by removing small portions of lamina and hypertrophic ligamentum flavum in a minimally invasive, outpatient procedure through an opening about the size of a baby aspirin...

9 Apr 2015

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer.

2 Apr 2015

Phone counseling can boost recovery, reduce pain in patients after spinal surgery

Research by Johns Hopkins scientists suggests that having a short series of phone conversations with trained counselors can substantially boost recovery and reduce pain in patients after spinal surgery.

1 Apr 2015

Zyga reports commercial use of modernized SImmetry Sacroiliac Joint Fusion System for low back pain

Zyga Technology, Inc., a medical device company focused on the design, development and commercialization of minimally invasive devices to treat underserved conditions of the lumbar spine, today announced the launch and first commercial use of an updated SImmetry Sacroiliac Joint Fusion System. The surgery was performed by Dr. Brett Menmuir.

27 Mar 2015

Back Pain News and Research

Latest Back Pain News and Research

New study finds growing use of CAM therapies among menopausal women

People across the world are living longer but spending more time in ill health

GBD analysis shows over 95% of global population has health problems

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

North American Spine Society issues formal coverage recommendation for MIS SI joint fusion

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Study shows link between upright locomotion and spinal health

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Two UC Davis researchers awarded grant to help improve surveillance for patients with small lung nodules

Board-certified physiatrist Brian Fellechner joins St. Luke’s University Health Network

ACA calls for 'conservative care first' approach to low-back pain

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Early and guideline adherent physical therapy reduces costs, resources in LBP patients

National study comparing minimally invasive lumbar decompression (mild) with epidural steroid injections (ESIs) reaches full enrollment

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Phone counseling can boost recovery, reduce pain in patients after spinal surgery

Zyga reports commercial use of modernized SImmetry Sacroiliac Joint Fusion System for low back pain

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Back Pain News and Research

Latest Back Pain News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in